GM-CSF With Post-Transplant Cyclophosphamide

Recruiting now · Phase 2

Conditions studied: Transplant-Related Hematologic Malignancy

In brief

Given the increased number of HLA-mismatched haploidentical transplantation with post-transplant cyclophosphamide performed each year and the high risk of infectious complications associated with this type of transplant, the investigators suggest that GM-CSF administration post-infusion of T-replete haploidentical stem cells and post-transplant cyclophosphamide can yield similar count recovery rates to G-CSF with a potential of lowering risk of infectious complications.

Key facts

Study ID

NCT04237623

Run by

Northside Hospital, Inc.

People needed

38

Starts

2020-05-18

Expected to finish

2026-09-18

Last updated by the study team

2026-04-16

Who can join

Age: 18 and older, up to 78. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Availability of 5/10 to 8/10 matched related donor
• KPS >/= 70%
• CML, AML, MDS, ALL, CLL, HD, NHL, MPS/CMML, MM, any other hematologic condition deemed an eligible indication for allogeneic transplant by the treating center

You may not qualify if…

• Poor cardiac, pulmonary, liver, and renal function
• HIV-positive
• Patients who have a debilitating medical or psychiatric illness that would preclude them from giving informed consent
• History of severe or serious allergic reaction to human GM-CSF or yeast-derived products

Where it is running

• Northside Hospital — Atlanta, Georgia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.